In today’s world, beauty is no longer a question of age. Women want their beauty to last into the future. That’s why TEOXANE Laboratories specialise in the complex development of hyaluronic acid injectable gels with researchers driven by the culture of excellence and innovation as well as a total dedication to effectiveness and safety. Thanks to this approach, the hyaluronic acid gels we produce in our Geneva-based laboratories are of the highest quality and purity.

Mrs Valérie Taupin
CEO & Founder TEOXANE
THE EYE CONTOUR: A PROMINENT DEMAND / A CHALLENGING AREA TO TREAT

An early and visible sign of facial ageing

- From the age of 30, 50% of women are concerned by the appearance of their under eye circles.
- Eye contour continues to be one of the major aesthetic concerns for women throughout their lifetime.
- It only is the 7th area corrected by aesthetic treatment.

"% of treatment preference by indication amongst 603 women"

WIN THE ULTIMATE BATTLE AGAINST UNDER EYE CIRCLES

REFERENCES

6. Data on File. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity.
8. Complementary analysis of the study 10E2047 TEOSYAL® PureSense Redensity [I]. Assessment of TEOSYAL® PureSense efficacy on skin rejuvenation and protection. Evaluation of the skin histology in healthy volunteers, on the measurement of the healing process in the area of injection.
9. Multicentric and international study, 2012/2013. 33 practitioners, 10% of women (56 women) and 25% of men (268 men). Val (%), median (IQR) [95% CI] (9) (9). Adverse events: generally mild (78%), occasionally moderate (17%) or more severe (6%). (n=112 patients available for safety interviews within 1 month). Reviewing the 10E2047 data, it has been shown that, in daily practice, 90% of patients were injected with the recommended dose. The 5% of patients who were injected with the maximum dose of 1 ml per side, only 1 showed a more severe event that was not assessed during follow-up. No severe events were recorded during the follow-up. In the 10E2047 study, the incidence of adverse events was less than 1?.
14. Phase III multicentric clinical study of 60 patients followed during 1 year (2010). The majority of patients were satisfied with the results immediately after injection, Visit 2 (T30 days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area, 5% in the crows feet and 2% in the nasolabial folds. 22% of patients have been in contact with a dermatologist in the past year. 10% of patients were satisfied with the results immediately after injection, Visit 2 (T30 days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area, 5% in the crows feet and 2% in the nasolabial folds. 22% of patients have been in contact with a dermatologist in the past year. 10% of patients were satisfied with the results immediately after injection.
20. Arcane Research Study – February 2011: study carried out in France among 4 402 women aged 18 to 75.
Anatomical specificities of the suborbital area
A medical challenge with a complex anatomy

High risk area due to:
- A delicate lymphatic system
- The angular artery
- The emergence of the infraorbital nerve (V2)

To treat this area physicians need:
- A product with specific properties
- A fully mastered injection technique


EYE CONTOUR SITUATION
EYE CIRCLE SOLUTION
More than meets the eye

3-in-1 patented formula
* of TEOXANE Laboratories products
FR1157848

REDENSITY
THE 1ST GEL SPECIFICALLY DESIGNED TO TACKLE UNDER EYE CIRCLES

**

Lidocaine 0.3%

A gel with unique properties
Low hygroscopy
Light consistency
Viscous with optimised cohesivity
Dermo stimulating
Anesthetising

➋

➌

Cocktail of 14 essential nutrients naturally present in the skin
8 Amino Acids for cell regeneration & hydration (Leu, Ile, Val, Gly, Lys, Thr, Pro, Arg)
3 antioxidants for protection against free radicals (Glutathione, N-Acetyl-L-Cystein, Alpha-Lipoic Acid)
2 minerals (Zinc, Copper) and 1 Vitamin (B6) for cellular metabolism

Good safety & ease of injection
Immediate & natural under eye correction
Delayed ageing of the eye contour

⪫

BDDE bonds

⪪

High Molecular Weight Hyaluronic Acid (HA) mix:
Crosslinked HA & Non crosslinked HA
Total HA concentration (15 mg/mL)

➊
A STATE-OF-THE-ART FILLER BASED ON THE REDENSITY FUNDAMENTALS

To improve safety & ease of injection

- Ideal viscoelasticity and gel cohesivity for a high spreadability & convenient positioning of the gel\(^6,9,10\)

- Lightweight with minimal gel swelling for low pressure on tissues and less risk of oedema\(^6,9,10\)

For immediate & natural correction\(^6,9,10\)

- Low hygroscopy for natural and reliable result: Volume injected = Correction observed
- Viscous with enhanced cohesivity for filling efficiency

To delay skin ageing\(^7,8,12\)

- Hydration & rejuvenation: from the complementary actions of diffusible essential nutrients and High Molecular Weight HA

- Redensification of the papillary dermis & the dermoepidermal junction

And more than that…

- Dermoepidermal junction strengthening - increased elasticity & firmness
  - +98% Collagen IV (elasticity & tissue cohesion)
  - +26% Fibrillin-1 (tensor effect)

- Antioxidant effect
  - -28% malondialdehyde (oxidative stress marker)

- Skin Hydration
  - x14 epidermal glycoaminoglycan production

---

Monophasic HA
24 mg/g

Teosyal Redensity [II]

Biphosphic HA
20 mg/g

Control

HA + Essential Nutrient Cocktail

Skin explants at day 9 post-injection

Prof. Giuseppe SITTO, M.D, Aesthetic Surgeon Milan, Turin and Naples

The tear trough has always been considered a difficult area to treat; both for its intrinsic nature and due to the difficulty in finding materials that are less hydrophilic. TEOSYAL® PureSense Redensity [II] can be used safely to achieve good results in this challenging area\(^1\).
It is well-known that the hygroscopic effect of HA is to retain water, making the treatment of this area difficult. Currently we have a specific HA, TEOSYAL® PureSense Rendensity [II], faintly hygroscopic, specifically designed to treat tear troughs and to correct them naturally on the long-term.

Dr. Natalia RIBE, M.D, Aesthetic Doctor & Andrologist Barcelona Spain.

- High improvement of under eye circles
- Recognised skin quality improvement
- % of patients with satisfactory to very satisfactory skin quality improvement one month post-injection

Evaluation of the overall aesthetic results by physicians and patients, over 12 months (% of improved scores on the Global Aesthetic Improvement Scale*)

- HYDRATION
- ELASTICITY
- RADIANCE
- QUALITY

<table>
<thead>
<tr>
<th></th>
<th>0%</th>
<th>20%</th>
<th>40%</th>
<th>60%</th>
<th>80%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>89%</td>
<td>89%</td>
<td>88%</td>
<td>89%</td>
<td>86%</td>
<td>87%</td>
</tr>
<tr>
<td>After</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
</tr>
</tbody>
</table>

**Physician opinion**

- 99% of patients and physicians perceived an aesthetic improvement of the tear trough within 1 month post-injection

**Patient opinion**

- An efficacy observed by 33 physicians and 151 patients

- Exceptional improvement
- Very improved result
- Improved result
- Unaltered patient (1%)
- Worsened result (0%)

A CLINICALLY OBSERVED EFFICACY ON THE UNDER EYE CIRCLE

**Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men). Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area.**

* based on GAIS: Global Aesthetic Improvement Scale.

You won’t believe your eyes

© TEOXANE
Safety recognised in a clinical trial 

During the clinical trial:

- Mainly mild and transient post-injection reactions
- No blue discoloration / Tyndall effect (> 1 month)
- No need for hyaluronidase
- No unpleasant malar swelling
- No extra local anaesthetics required

An easy injection for a reliable practice

75% of the patients reported no adverse event within 1 month post-injection.

Most side effects reported were mild, temporary and correctable.

Ease of injection reported by 98% of physicians.

A PROVEN PATIENTS’ AND PHYSICIANS’ SATISFACTION

CLINICAL SAFETY & SATISFACTION

Easy on the eye

Comparison of the safety with published literature. Side effects of the treatment: 11% bruising is significantly lower than the 27% reported by (15). 2,6% initial blue discoloration is lower than the 5% reported by (16). Careful massage of the highly malleable gel ensures accurate spreading and prevents the lumpiness or surface irregularities observed in (16,17). 8% early transient oedema is substantial lower than previously reported (10).

**Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men). Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area.**

Adverse events (Swelling 11.6% - Bruising 10.7% - Redness 6.3% - Blue discoloration 0.9% - Other 1.8%) 61% 2% 37%

- Other
- Very Easy
- Easy

High global patient satisfaction levels

- 97% of satisfied patients
- 98% of patients would recommend the procedure
- 97% of patients would repeat the treatment

25% 75%
3  Precise injection technique

- SMALL volume
  - max 0.5mL per eye circle
- SLOW injection
- DEEP supra-periosteal / sub-orbicular injection

4  Protocol

- First session:
  - under-correction is recommended
- Touch-up session:
  - 1 month later, only if necessary

Caution

CONTRAINDICATION

- Lower eyelid looseness
- Lymphatic stasis
- Very serious depression in the tear trough
- Significant malar or palpebral bags

HIGH RISK AREAS

- Angular artery
- Emergence of the infraorbital nerve V2

Anatomical section of the under eye area

Microbolus technique with needle

Retrograde technique with cannula

PROTOCOL: 4 KEY SUCCESS FACTORS

- Diagnosis at physician’s discretion. Read instructions for use

1  4 indications

- Under eye circle
- Tear trough
- Palpebromalar groove
- Minimal palpebral or malar bag

2  Careful clinical diagnosis* of the lower eyelid area

- Examine patient in a semi-sitting position

  - STEP 1 / Pressure test: press the lower orbital margin to validate the absence of lymphatic stasis
  - STEP 2 / Snap-Back test: check the absence of skin looseness at the lower eyelid level (grade 1)
  - STEP 3 / Positive vectors theory: control the vector, the lower eyelid should have a negative vector
  - STEP 4 / Gel volume estimation: ask the patient to look upwards then exert pressure on the malar bone

1

Tutorials videos on TEOXANE’s Youtube channel

www.teoxane.com

Teoxane Redensity2 brochure-interieur-GB.indd   10-11
19/09/2016   17:37
TEOSYAL® PURESENSE REDENSITY II

A different gel designed for eye circles

- Mix of cross-linked and non cross-linked HA
- HA concentration: 15 mg/mL
- Cross-linking:
  - Lidocaine 0.3%
  - Essential Nutrient Complex
- Box of 2 x 1 mL syringes + 30G ½ needle

CE marking class III

TEOSYAL® PEN

THE FIRST MOTORISED CORDLESS HA INJECTION SYSTEM

Let your art speak. Thanks to its ergonomic, lightweight design and homogenous filler delivery, TEOSYAL® PEN offers you a greater ease of injection in sensitive areas and a smoother experience for your patient.

TEOSYAL® PEN is a motorised and cordless device for hyaluronic acid injections in order to correct wrinkles and depressions.

Manufactured by Juvaplus SA. This medical device (class IIa), is a regulated health product which bear, under this regulation, the CE mark (CE0434).

TEOSYAL REDENSITY® is a trademark of TEOXANE SA and it is a product of the range TEOSYAL® PURESENSE. TEOSYAL® PureSense Redensity II is a medical device, class III, and is regulated health product bearing the CE marking (CE0086) under this regulation. For more information, please refer to TEOSYAL® PureSense Redensity II’s instructions for use.

FOR AN EASIER TREATMENT OF THE EYE CIRCLE:

REDENSITY II + TEOSYAL® PEN